Ashvattha therapeutics announces first patient dosed via subcutaneous administration of anti-angiogenic therapeutic d-4517.2 for wet amd and dme in phase 2 chronic dosing study

Redwood city, calif., nov. 01, 2023 (globe newswire) -- ashvattha therapeutics (“ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that the first patient has been dosed with d-4517.2, a subcutaneously administered anti-angiogenic therapeutic, in a phase 2 chronic dosing study. the open-label study will evaluate the safety and efficacy of chronic d-4517.2 dosing in patients with wet amd and dme.
AMD Ratings Summary
AMD Quant Ranking